These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 7105059

  • 1. Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Slayton RE, Blessing JA, Delgado G.
    Cancer Treat Rep; 1982 Aug; 66(8):1669-71. PubMed ID: 7105059
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
    Slayton RE, Blessing JA, Homesley HD.
    Cancer Treat Rep; 1984 Dec; 68(12):1513-4. PubMed ID: 6509456
    [No Abstract] [Full Text] [Related]

  • 4. Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study.
    Slayton RE, Blessing JA, Angel C, Berman M.
    Cancer Treat Rep; 1987 Dec; 71(12):1303-4. PubMed ID: 3690545
    [No Abstract] [Full Text] [Related]

  • 5. Phase II trial of etoposide in the management of advanced or recurrent squamous cell carcinoma of the vulva and carcinoma of the vagina: a Gynecologic Oncology Group Study.
    Slayton RE, Blessing JA, Beecham J, DiSaia PJ.
    Cancer Treat Rep; 1987 Sep; 71(9):869-70. PubMed ID: 3621221
    [No Abstract] [Full Text] [Related]

  • 6. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
    Slayton RE, Creasman WT, Petty W, Bundy B, Blessing JA.
    Cancer Treat Rep; 1979 Sep; 63(11-12):2089-92. PubMed ID: 526942
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
    Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA.
    Cancer Treat Rep; 1979 Jan; 63(1):21-7. PubMed ID: 369691
    [Abstract] [Full Text] [Related]

  • 9. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Rose PG, Blessing JA, Soper JT, Barter JF.
    Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
    [Abstract] [Full Text] [Related]

  • 10. Oral etoposide in gestational trophoblastic disease.
    Wong LC, Choo YC, Ma HK.
    Cancer Treat Rep; 1984 May; 68(5):775-7. PubMed ID: 6327035
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase II trial of etoposide in advanced prostate cancer.
    Trump DL, Loprinzi CL.
    Cancer Treat Rep; 1984 Sep; 68(9):1195-6. PubMed ID: 6478456
    [No Abstract] [Full Text] [Related]

  • 13. Phase II study of etoposide in the treatment of esophageal carcinoma.
    Coonley CJ, Bains M, Heelan R, Dukeman M, Kelsen DP.
    Cancer Treat Rep; 1983 Apr; 67(4):397-8. PubMed ID: 6850656
    [No Abstract] [Full Text] [Related]

  • 14. Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract.
    Kelsen DP, Magill GB, Cheng E, Dukeman M, Sordillo P, Heelan R, Yagoda A.
    Cancer Treat Rep; 1983 May; 67(5):509-10. PubMed ID: 6850667
    [No Abstract] [Full Text] [Related]

  • 15. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
    Rose PG, Blessing JA, Lewandowski GS, Creasman WT, Webster KD.
    Gynecol Oncol; 1996 Oct; 63(1):101-4. PubMed ID: 8898177
    [Abstract] [Full Text] [Related]

  • 16. Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
    Gockerman JP, Bartolucci AA, Nelson MO, Silberman H, Velez-Garcia E, Stein R.
    Cancer Treat Rep; 1986 Jun; 70(6):801-2. PubMed ID: 3524829
    [No Abstract] [Full Text] [Related]

  • 17. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG, Blessing JA, Van Le L, Waggoner S.
    Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
    [Abstract] [Full Text] [Related]

  • 18. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
    Vaughn CB, Panettiere F, Thigpen T, Bottomley R, Hoogstraten B, Samal B.
    Cancer Treat Rep; 1981 Aug; 65(5-6):443-5. PubMed ID: 7237465
    [No Abstract] [Full Text] [Related]

  • 19. Phase II clinical trial of VP-16-213 in ovarian cancer.
    Maskens AP, Armand JP, Lacave AJ, De Jager RL, Hansen HH, Wolff JP.
    Cancer Treat Rep; 1981 Aug; 65(3-4):329-30. PubMed ID: 7016320
    [No Abstract] [Full Text] [Related]

  • 20. [Etoposide in the treatment of recurrent malignant lymphoma].
    Háber J, Klener P.
    Vnitr Lek; 1986 Apr; 32(4):379-85. PubMed ID: 3727425
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.